Earnings call transcript: Centene Q2 2025 results reveal EPS miss, stock rises

Centene Corporation (CNC) reported a significant Q2 2025 adjusted loss per share of $0.16, missing analyst forecasts, primarily due to a substantial $2.4 billion headwind from marketplace risk adjustments and a $2.1 billion headwind from elevated Medicaid medical costs. Despite the earnings miss, the stock rose 6.09% in after-hours trading, driven by robust revenue of $48.74 billion, which exceeded expectations, and investor confidence in management's strategic response. The company has lowered its full-year 2025 adjusted EPS guidance to $1.75 but is actively repricing its Marketplace book for 2026 profitability and expects to secure improved Medicaid rates, while the Medicare segment shows favorability, signaling anticipated margin improvements across all business lines by 2026.

Analysis

Centene Corporation (CNC) reported a severe Q2 2025 earnings dislocation, with an adjusted loss per share of $0.16 against a forecasted EPS of $0.23, leading to a drastic reduction in full-year 2025 adjusted EPS guidance to $1.75 from a prior $7.25. The miss was driven by two significant headwinds: a $2.4 billion full-year impact from a mispriced Marketplace risk pool, where program integrity measures led to a higher-morbidity membership, and a $2.1 billion impact from an elevated Medicaid Health Benefits Ratio (HBR) of 94.9%, fueled by cost trends in behavioral health and high-cost drugs. Despite these substantial operational challenges, the company's stock rose 6.09% post-announcement, a reaction fueled by a 10.17% revenue beat to $48.74 billion and management's decisive recovery plan. The strategy hinges on aggressively repricing 100% of the Marketplace portfolio for 2026 profitability and securing improved Medicaid rates, with 88% of that book rerating by early 2026. A $700 million pretax favorability in the Medicare segment provides a partial offset, indicating that while current financials are deeply stressed, the market is pricing in a successful execution of this turnaround.

Key Decisions for Investors

• The investment thesis for Centene now hinges entirely on execution risk; investors should closely monitor the Medicaid HBR trajectory in the second half of 2025 and any management commentary on the success of Marketplace repricing for 2026.
• Given the market's forward-looking reaction, the current valuation may offer an attractive entry point for investors confident in management's ability to restore profitability by 2026, but short-term volatility should be expected.
• Monitor external regulatory developments closely, as the success of the turnaround is highly dependent on favorable state-level Medicaid rate updates and the final impact of federal program integrity measures on the 2026 Marketplace risk pool.
• Despite the significant earnings pressure, the company's capital position appears stable with a largely undrawn credit facility and a 39% debt-to-cap ratio, providing a financial cushion to navigate the operational challenges without an immediate need for capital raises.